Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS

Amyotrophic Lateral Sclerosis

Volumn 13, Issue 1, 2012, Pages 1-10

  Otto, Markus ^a   Bowser, Robert ^b   Turner, Martin ^c   Berry, James ^d   Brettschneider, Johannes ^a   Connor, James ^e   Costa, Jlia ^f   Cudkowicz, Merit ^d   Glass, Jonathan ^g   Jahn, Olaf ^h   Lehnert, Stefan ^a   Malaspina, Andrea ⁱ   Parnetti, Lucilla ^j   Petzold, Axel ^k,l   Shaw, Pamela ^m   Sherman, Alexander ^d   Steinacker, Petra ^a   Sßmuth, Sigurd ^a   Teunissen, Charlotte ^l   Tumani, Hayrettin ^a   Wuolikainen, Anna ⁿ   Ludolph, Albert ^a   more..

^a UNIVERSITY OF ULM   (Germany)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^j UNIVERSITY OF PERUGIA   (Italy)

^k NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁿ UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

Biobank; Biomarker; Brain bank; Cerebrospinal fluid; Proteomics

Indexed keywords

BIOLOGICAL MARKER; DNA; NEUROCHEMICAL MARKER; RNA; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOPSY; BIOBANKING; BLOOD SAMPLING; CEREBROSPINAL FLUID; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DNA DETERMINATION; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; HUMAN; INFORMED CONSENT; LIPIDOMICS; LONGITUDINAL STUDY; METABOLOMICS; MOLECULAR DIAGNOSIS; MUSCLE BIOPSY; PATIENT MONITORING; PHENOTYPE; POSTTRANSCRIPTIONAL GENE SILENCING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; QUALITY CONTROL; REVIEW; RNA ANALYSIS; SALIVA ANALYSIS; SKIN BIOPSY; STANDARD OPERATING PROCEDURE; URINALYSIS;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; HUMANS; PROTEOMICS;

EID: 84855410186     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2011.627589     Document Type: Review

References (42)

1. Poser CM, Johnson M, Bunch LD. Serum Amino Acid Studies in Amyotrophic Lateral Sclerosis I. Results of Arginine Tolerance Tests. Arch Neurol. 1965;12:604-9.
2. Bowser R, Lacomis D. Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve. 2009;40:753-62.
3. Ryberg H, Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics. 2008;5:249-62. (Pubitemid 351670929)
4. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8:94-109.
5. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011 (Early Online Publication, February 7 2011).
6. Poste G. Bring on the biomarkers. Nature. 2011;469: 156-7.
7. Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, et al. Towards a neuroimaging biomar-ker in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:400-3.
8. Sherman A, Bowser R, Grasso D, Power B, Milligan C, Jaffa M, et al. Proposed BioRepository platform solution for the ALS research community. Amyotroph Lateral Scler. 2011;12:11-6.
9. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914-22.
10. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852-6. (Pubitemid 43739759)
11. Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011;117:528-37.
12. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183-98. (Pubitemid 40804835)
13. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009;111:1182-91.
14. Jesse S, Brettschneider J, Sussmuth SD, Landwehrmeyer BG, von Arnim CA, Ludolph AC, et al. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol. 2011;258:1034-41.
15. Zetterberg H, Tullhog K, Hansson O, Minthon L, Londos E, Blennow K. Low incidence of post-lumbar puncture headache in 1089 consecutive memory clinic patients. Eur Neurol. 2010;63:326-30.
16. Ranganathan S, Polshyna A, Nicholl G, Lyons-Weiler J, Bowser R. Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling. Clin Pro-teomics. 2006;2:91-101.
17. Rosenling T, Slim CL, Christin C, Coulier L, Shi S, Stoop MP, et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteome Res. 2009;8:5511-22.
18. Wuolikainen A, Hedenstrom M, Moritz T, Marklund SL, Antti H, Andersen PM. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotroph Lateral Scler. 2009;10:229-36.
19. Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37:234-44. (Pubitemid 351494195)
20. Wong M, Martin LJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in trans-genic mice. Hum Mol Genet. 2010;19:2284-302.
21. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-86.
22. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, et al. Brain protein preservation largely depends on the post mortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol. 2007;66:35-46. (Pubitemid 46066787)
23. Durrenberger PF, Fernando S, KashefiSN, Ferrer I, Hauw JJ, Seilhean D, et al. Effects of ante mortem and post mortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol. 2010;69:70-81.
24. Steinacker P, Rist W, Swiatek-de-Lange M, Lehnert S, Jesse S, Pabst A, et al. Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. Proteomics. 2010;10: 81-9.
25. Tumani H, Lehmensiek V, Lehnert S, Otto M, Brettschnei-der J. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev Proteomics. 2010;7:29-38.
26. Geiger T, Wisniewski JR, Cox J, Zanivan S, Kruger M, Ishi-hama Y, et al. Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteom-ics. Nat Protoc. 2011;6:147-57.
27. Patel VJ, Thalassinos K, Slade SE, Connolly JB, Crombie A, Murrell JC, et al. A comparison of labeling and label-free mass spectrometry-based proteomics approaches. J Pro-teome Res. 2009;8:3752-9.
28. Ramstrom M, Ivonin I, Johansson A, Askmark H, Markides KE, Zubarev R, et al. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatog-raphy-Fourier transform ion cyclotron resonance mass spec-trometry. Proteomics. 2004;4:4010-8. (Pubitemid 39662757)
29. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2009;72:14-9.
30. Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve. 2010;42:95-103.
31. Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry. 2009;15:1088-100.
32. Brechlin P, Jahn O, Steinacker P, Cepek L, Kratzin H, Lehnert S, et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics. 2008;8:4357-66.
33. Guerrier L, Righetti PG, Boschetti E. Reduction of dynamic protein concentration range of biological extracts for the discovery of low-abundance proteins by means of hexapep-tide ligand library. Nat Protoc. 2008;3:883-90. (Pubitemid 351639032)
34. Mouton-Barbosa E, Roux-Dalvai F, Bouyssie D, Berger F, Schmidt E, Righetti PG, et al. In-depth exploration of cer-ebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. Mol Cell Proteomics. 2010;9:1006-21.
35. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4:222.
36. Espina V, Heiby M, Pierobon M, Liotta LA. Laser capture microdissection technology. Expert Rev Mol Diagn. 2007;7:647-57. (Pubitemid 47547729)
37. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009;326:1549-54.
38. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics. 2005;1:101-8. (Pubitemid 40778831)
39. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS One. 2011;6:17947.
40. Sansone SA, Fan T, Goodacre R, Griffin JL, Hardy NW, Kaddurah-Daouk R, et al. The metabolomics standards initiative. Nat Biotechnol. 2007;25:846-8.
41. Quinn PJ, Rainteau D, Wolf C. Lipidomics of the red cell in diagnosis of human disorders. Methods Mol Biol. 2009;579:127-59.
42. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomar-ker of dietary intake. Prog Lipid Res. 2008;47:348-80.